Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials
Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN, Chilcott J
Journal of internal medicine · 165 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2008-12-23 · J Intern Med · vol. 265 · número 5 · págs. 568–580
- Editorial
- Wiley
- Citado
- 228 citas · más que el 81% de estudios similares · 1.5× el promedio de su campo
- Referencias
- 46 trabajos
- Acceso
- De pago
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Cholesterol and Lipid Metabolism · Blood Pressure and Hypertension Studies
- Palabras clave
- ezetimibe, hypercholesterolemia, LDL cholesterol lowering, lipid-lowering therapy, monotherapy, heterozygous familial hypercholesterolemia, triglycerides, HDL cholesterol, drug safety, cholesterol absorption inhibitors
- MeSH
- humans, hypercholesterolemia, azetidines, cholesterol, triglycerides, anticholesteremic agents, treatment outcome, cholesterol, ldl, cholesterol, hdl, randomized controlled trials as topic, ezetimibe
8 autores
- Abdullah Pandor🇬🇧University of Sheffield
- Roberta Ara
- Indra Tumur
- Anna Wilkinson🇬🇧University of Sheffield
- Suzy Paisley
- Alejandra Duenas
- Paul N. Durrington🇬🇧University of Manchester
- James B. Chilcott
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
To study the evidence on the efficacy and safety of ezetimibe monotherapy for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia.
Design
Systematic review and meta-analysis of randomized controlled trials (RCTs).
Methods
Eleven electronic bibliographic databases covering the biomedical, scientific and grey literature were searched from inception and supplemented by contact with experts in the field. Two reviewers independently determined the eligibility of RCTs, with a minimum treatment duration of 12 weeks, which compared ezetimibe monotherapy (10 mg per day) with placebo.
Results
In the absence of data from clinical outcome trials, surrogate endpoints such as changes in lipid concentrations were used as indicators of clinical outcomes. A meta-analysis of eight randomized, double-blind, placebo-controlled trials (all 12 weeks) showed that ezetimibe monotherapy was associated with a statistically significant mean reduction in LDL cholesterol (from baseline to endpoint) of -18.58%, (95% CI: -19.67 to -17.48, P < 0.00001) compared with placebo. Significant (P < 0.00001) changes were also found in total cholesterol (-13.46%, 95% CI: -14.22 to -12.70), HDL cholesterol (3.00%, 95% CI: 2.06-3.94) and triglyceride levels (-8.06%, 95% CI: -10.92 to -5.20). Ezetimibe monotherapy appeared to be well tolerated with a safety profile similar to placebo.
Conclusions
In a meta-analysis restricted to short-term trials in hypercholesterolaemia, significant potentially favourable changes in lipid and lipoprotein levels relative to baseline occurred with ezetimibe monotherapy. Further long-term studies with cardiovascular and other clinical outcome data are needed to assess the efficacy and safety of ezetimibe more fully.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.